Mirikizumab—A Narrative Review of LUCENT Trials

Introduction: Ulcerative colitis (UC) falls under the spectrum of inflammatory bowel disease, presents with bloody diarrhea and abdominal pain, and is diagnosed endoscopically with erosive lesions in the colon. Salicylates and steroids form the cornerstone of the treatment, but severe and resistant diseases warrant biological therapy. Methods: LUCENT 1 - 3 trials, for approval of Mirikizumab, a p-19 subunit antagonist on IL-23, were included in this review. Discussion: Mirikizumab outperformed placebo in the induction trial (LUCENT-1), with notably higher rates of clinical remission. In the maintenance phase (LUCENT-2), mirikizumab had sustained efficacy, with significant proportions achieving and maintaining clinical remission up to week 104. In LUCENT-3, which documented the 104-week follow-up period, mirikizumab exhibited lasting efficacy in maintaining clinical response and remission from weeks 52 to 104. Conclusions: This narrative review offers insight into the trial, its structure, and ultimate findings. Mirikizumab emerges as a potent biological therapy for UC.